Results 41 to 50 of about 6,744 (185)

Investigating the Role of Type I Interferon Signaling on Muscle Disease Using Mouse Models

Arthritis &Rheumatology, EarlyView.
Objective Dysregulated type I interferon (IFN) signaling contributes to autoimmune myositis pathogenesis. We investigated the therapeutic effects of JAK inhibitors in two mouse models. We also examined how type I IFNs affect muscle vasculature. Methods Myositis was induced in major histocompatibility complex class I double transgenic ([TRE‐H‐2Kb (H ...
Rita Spathis, Sabrina Narvesen, Deeva Robles Kuriplach, Karen Huang, Teja Sundar, Elizabeth Bagley, Joanna Parkes, Xinyu Jia, Nandhana Sudhan, Alfredo Guzman, Kanneboyina Nagaraju, Melissa Morales   +11 more
wiley   +1 more source

Platelet proteome and function in X−linked thrombocytopenia with thalassemia and in silico comparisons with gray platelet syndrome

Haematologica, 2020
In X-linked thrombocytopenia with thalassemia (XLTT; OMIM 314050), caused by the mutation p.R216Q in exon 4 of the GATA1 gene, male hemizygous patients display macrothrombocytopenia, bleeding diathesis and a b-thalassemia trait.
Daniel Bergemalm, Sofia Ramström, Caroline Kardeby, Kjell Hultenby, Anna Göthlin Eremo, Carina Sihlbom, Jörgen Bergström, Jan Palmblad, Maria Åström   +8 more
doaj   +1 more source

First‐in‐human, phase I, randomized, safety, pharmacokinetic, food‐effect and pharmacodynamic study of a tyrosine kinase 2/Janus kinase 1 inhibitor, SDC‐1801

British Journal of Clinical Pharmacology, EarlyView.
Aim The purpose of this study is to evaluate safety, tolerability, pharmacokinetics (PK), food‐effect (FE) and pharmacodynamics (PD) of an oral tyrosine kinase‐2 (TYK2)/Janus kinase‐1 (JAK1) inhibitor, SDC‐1801, in healthy adult participants. Methods This first‐in‐human study randomized 95 male and female participants.
Chris Brearley, Sam Francis, John Reader, Judi Proctor   +3 more
wiley   +1 more source

Development of thrombopoietin receptor agonists for clinical use [PDF]

Journal of Thrombosis and Haemostasis, 2009
Thrombopoietin (TPO) is an essential hematopoietic cytokine for megakaryopoiesis. In 2002, we demonstrated that pegylated-recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) increased platelet counts in patients with chronic immune thrombocytopenic purpura (ITP) in a Phase I/II clinical trial.
Y, Ikeda, Y, Miyakawa
openaire   +2 more sources

Use of Thrombopoietin Receptor Agonists in Pregnancy

Hematology/Oncology and Stem Cell Therapy, 2022
The management of immune thrombocytopenic purpura (ITP) involves several lines of therapy such as corticosteroids and intravenous immunoglobulin. With the emergence of novel therapies such as thrombopoietin receptor agonists (TPO-RAs), there has been a shift in treatment modalities.
Jude, Howaidi, Abdullah M, AlRajhi, Ali, Howaidi, Fouad H, AlNajjar, Imran K, Tailor   +4 more
openaire   +2 more sources

Harnessing blood clot as a native scaffold for orchestrating tissue repairs and regeneration

BMEMat, EarlyView.
The blood clot, owing to its dynamic composition and unique microenvironment, holds significant yet underappreciated potential for tissue engineering. This review systematically summarizes the pathophysiology of clot formation, the key regulatory factors shaping its microenvironment, and its applications in both pre‐clinical and clinical settings ...
Gao‐peng Dang, Yu‐zhu Wang, Yi‐fei Wang, Que Bai, Jia‐xin Hao, Zhi‐ting Li, Xiao‐qing Cao, Yu Wei, Yue Feng, Ji‐hua Chen, Franklin R. Tay, Rui‐bing Wang, Jun‐ting Gu, Li‐na Niu   +13 more
wiley   +1 more source

Commonalities of platelet dysfunction in heart failure with preserved ejection fraction and underlying comorbidities

ESC Heart Failure, Volume 12, Issue 2, Page 1013-1028, April 2025.
Abstract Heart failure with preserved ejection fraction (HFpEF) is characterized by a lack of a specific targeted treatment and a complex, partially unexplored pathophysiology. Common comorbidities associated with HFpEF are hypertension, atrial fibrillation, obesity and diabetes.
Giorgia D'Italia, Blanche Schroen, Judith M.E.M. Cosemans   +2 more
wiley   +1 more source

Thrombocytosis and tumour distribution predict outcome in dogs with hepatocellular carcinoma: A multi‐institutional retrospective analysis

Veterinary Record, EarlyView.
Abstract Background Hepatocellular carcinoma (HCC) is the most common canine hepatobiliary tumour. This study aimed to determine which criteria influenced outcome of HCC in a modern population of dogs across eight institutions. Methods The medical records of 106 dogs with HCC were retrospectively reviewed.
Emily A. Janik, MacKenzie A. Pellin, Dawn M. Clarke   +2 more
wiley   +1 more source

Avatrombopag for the treatment of immune thrombocytopenia and thrombocytopenia of chronic liver disease

Journal of Blood Medicine, 2019
Abraham Z Cheloff, Hanny Al-Samkari Division of Hematology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USACorrespondence: Hanny Al-SamkariDivision of Hematology, Massachusetts General Hospital, Suite 118, Room 112, Zero Emerson ...
Cheloff AZ, Al-Samkari H
doaj  

Update on Non‐Biological and RNA‐Based Therapeutics in Chronic Inflammatory Diseases: Precision Medicine Through Small Molecules: An EAACI Position Paper

Allergy, EarlyView.
ABSTRACT In the last decades, critical advancements in research technology and knowledge on disease mechanisms steered therapeutic approaches for chronic inflammatory diseases towards unprecedented target specificity. For allergic and chronic lung diseases, biologic drugs pioneered this goal, acquiring on the way—through the clinical use of monoclonal ...
F. Roth‐Walter, I. M. Adcock, C. Benito‐Villalvilla, R. Bianchini, L. Bjermer, G. Caramori, L. Cari, K. F. Chung, Z. Diamant, I. Eguiluz‐Gracia, E. F. Knol, M. Jesenak, F. Levi‐Schaffer, G. Nocentini, L. O'Mahony, O. Palomares, F. Redegeld, M. Sokolowska, B. Van Esch, M. Zurlo, C. Stellato   +20 more
wiley   +1 more source